.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,811,767

« Back to Dashboard

Details for Patent: 6,811,767

Title: Liquid droplet aerosols of nanoparticulate drugs
Abstract:There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
Inventor(s): Bosch; H. William (Bryn Mawr, PA), Ostrander; Kevin D. (Reading, PA), Cooper; Eugene R. (Berwyn, PA)
Assignee: Elan Pharma International Limited (Shannon, IE)
Filing Date:Jun 19, 2000
Application Number:09/597,738
Claims:1. An aerosol composition of an aqueous dispersion of nanoparticulate drug particles, wherein: (a) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle, wherein (i) the drug has a solubility in said aqueous dispersion of less than about 10 mg/mL; (ii) the drug is selected from the group consisting of, naproxen, triamcinolone acetonide, budesonide, and an anti-emetic; and (iii) the drug is present in a concentration of from about 0.05 mg/mL up to about 600 mg/mL; (b) the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) less than or equal to about 100 microns; (c) the nanoparticulate drug particles have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface of the drug, and (d) the aerosol composition can administer a drug dosage in less than about 15 seconds.

2. The aerosol composition of claim 1, wherein the composition is suitable for administration of a drug dosage in about 1 to 2 seconds.

3. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size of less than about 400 nm.

4. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size of less than about 300 nm.

5. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size of less than about 250 nm.

6. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size of less than about 100 nm.

7. The aerosol composition of claim 1, wherein the nanoparticulate drug particles have an effective average particle size of less than about 50 nm.

8. The aerosol composition of claim 1, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/mL or more, about 100 mg/mL or more, about 200 mg/mL or more, about 400 mg/mL or more, and about 600 mg/mL.

9. The aerosol composition of claim 1, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of about 2 to about 10 microns.

10. The aerosol composition of claim 9, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of from about 2 to about 6 microns.

11. The aerosol composition of claim 1, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of less than about 2 microns.

12. The aerosol composition of claim 1, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of about 5 to about 100 microns.

13. The aerosol composition of claim 12, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of about 30 to about 60 microns.

14. A method of administering to a patient an aerosol composition of an aqueous dispersion of nanoparticulate drug particles, wherein; (a) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle, wherein (i) the drug has a solubility in said aqueous dispersion of less than about 10 mg/mL; (ii) the drug is selected from the group consisting of naproxen, triamcinolone acetonide, budesonide, and an anti-emetic; and (iii) the drug is present in a concentration from about 0.05 mg/mL up to about 600 mg/mL; (b) the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) less than or equal to about 100 microns; and (c) the nanoparticulate drug particles have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface of the drug; and wherein the patient delivery time for the aerosol administration is about 15 seconds or less.

15. The aerosol composition of claim 1, wherein at least 70% of the drug particles have a particle size of less than about 1000 nm.

16. The aerosol composition of claim 1, wherein at least 90% of the drug particles have a particle size of less than about 1000 nm.

17. The method of claim 14, wherein the patient delivery time for the aerosol administration is about 1 to 2 seconds.

18. The method of claim 14, wherein the nanoparticulate drug particles have an effective average particle size of less than about 400 nm.

19. The method of claim 14, wherein the nanoparticulate drug particles have an effective average particle size of less than about 300 nm.

20. The method of claim 14, wherein the nanoparticulate drug particles have an effective average particle size of less than about 250 nm.

21. The method of claim 14, wherein the nanoparticulate drug particles have an effective average particle size of less than about 100 nm.

22. The method of claim 14, wherein the nanoparticulate drug particles have an effective average particle size of less than about 50 nm.

23. The method of claim 14, wherein the aerosol comprises a concentration of a drug selected from the group consisting of about 10 mg/mL or more, about 100 mg/mL or more, about 200 mg/mL or more, about 400 mg/mL or more, and about 600 mg/mL.

24. The method of claim 14, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of about 2 to about 10 microns.

25. The method of claim 24, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of from about 2 to about 6 microns.

26. The method of claim 14, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of less than about 2 microns.

27. The method of claim 14, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of about 5 to about 100 microns.

28. The method of claim 27, wherein the droplets of the aerosol have a mass median aerodynamic diameter (MMAD) of about 30 to about 60 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc